Immunocore in Oxford (UK) has been Granted Orphan Drug Designation for a Phase I Super rare Eye cancer drug by the FDA.
Uveal melanoma is a rare disease in which cancer cells form in the tissues of the eye, and comprises approximately 3% of all melanomas. It is actually the primary intraocular malignancy of the adult eye and currently, there are no effective treatments on the market for this debilitating disease.
Primary treatment has involved enucleation for a long time (such as in the Helsinki Long term study of Uveal Melanoma), so clearly there is a strong demand for an alternative, less scarring form of therapy.
Immunocore is one such biotech we ranked as our Top 10 to watch this Year, so we interviewed their CBO Eva-Lotta last month, and it seems their ImmTAC platform is certainly something to be interested in. Certainly, they were one of the 3 Major Biotechs which ‘overperformed’ last year too, with new partnerships and major progress in pipelines.